Swiss cannabis operator with EU-GMP compliant facility seeks strategic partner to become a dominant force in the EU
A Swiss cannabis cultivator and processor, supplying premium cannabis flowers and extracts to the pharmaceutical market, is seeking a strategic equity partner to fuel its continued growth. Positioned to become a leading player in the European cannabis industry, the company is primed for rapid expansion.
Listing ID:
16830162284
Licence(s) Held:
GACP, SwissMedic - medical cannabis license for cultivation and distribution and pending EU-GMP certification
Seeking equity partner to invest CHF 6 million in exchange for a 20% stake in the company to support ongoing expansion and growth. Open to bridge loan finance or other M&A options.
Listing Details:
A Swiss pharma-centric medical cannabis company specializing in indoor production and distribution of premium, high-quality, medical cannabis flowers
The company operates in a purpose built, 10,000 m² leased facility, featuring 25 grow rooms, state-of-the-art chemistry and biology labs, and a GMP-certified cleanroom for microbiological testing of finished products.
The company is currently operating the initial production phase and is generating revenue with secured contracts totaling CHF 7 million
Full production commences in Q1 2025, with expected sales ramping up to CHF 40 million and a target of CHF 70 million by 2026 through the addition of cannabis extraction and branded product launches
Has invested between 60 and 70 million CHF to build out the entire site
Company is waiting to obtain EU-GMP certification, which is expected imminently
Experienced, industry-leading international team with deep expertise navigating global medical cannabis markets
Company aims to secure a leading position in the DACH region (Germany, Austria and Switzerland) and globally, emphasizing R&D and sustainability to establish a strong position in the medical cannabis market and build consumer trust through the promotion of cannabis-based health benefits
Company has secured several initial offtake agreements, ensuring timely, efficient and continuous production and distribution of medical cannabis
Investing in the company will facilitate the development of a full-scale production process and secure additional offtake agreements to fully utilize the annual capacity of 18 tons
Seeking an equity partner to invest up to 6 million CHF in exchange for a stake in the company, with funds allocated to launch GMP-certified indoor cannabis production facility. Open for bridge loan or full divestiture opportunities.
16830162284
NEW CANNABIS BUSINESSES FOR SALE
See the latest cannabis business listings on the market including dispensaries, cultivation facilities, greenhouses, labs, and more. If you're looking to invest, acquire, or expand, these business opportunities provide the perfect starting point to grow your footprint in the cannabis industry.
36324927098
Licensed Colombian medical cannabis platform targeting EU pharmaceutical market seeks $3M equity partner
Premium, fully licensed Colombian cannabis cultivation platform offering pharmaceutical-grade production at industry-leading costs, with secured European market access and scalable growth potential
29345918591
State-of-the-art, ~130,000 sq. ft. production facility with 20.5 tonnes annual capacity and & EU-GMP designed processing hub
Opportunity to acquire a custom-designed, ~130,000 sq. ft. turnkey production asset including 84,000 square feet of canopy designed for pharmaceutical-grade output. This unique opportunity allows for a clean-slate acquisition of world-class infrastructure providing an immediate entry point into the global medicinal and premium international markets.